A public private partnership
Strategic Vaccines is a public private partnership to test and deploy FLOVID-20, an inhaled treatment for COVID-19 designed to keep COVID positive patients out of the hospital.
About Strategic Vaccines
Early treatment after a positive COVID-19 test
Targeted immunotherapy via selective T-cell stimulation is a game-changing medical breakthrough.
FLOVID-20 deploys this innovative technology to treat and protect asymptomatic patients with positive COVID-19 tests.
Watch this video to learn more about the treatment gap between vaccination and in-hospital care.
Under Development, FDA Approval Required
Currently Manufacturing in Solon, Ohio
Our targeted T-cell immunotherapy is currently being manufactured at Oakwood Laboratories, and we’re planning to conduct clinical studies in Cleveland.
Tested at the Galveston National Laboratory, we were able to prevent pneumonia in primates by giving them FLOVID-20 by inhalation then infecting them with COVID-19.
Watch the video below to see how we used our targeted T-cell immunotherapy to deliver FLOVID-20 by inhalation to protect primates from COVID-19 infection.
Targeted T-Cell Immunotherapy
Our targeted T-cell immunotherapy delivery platform offers a unique solution in identifying and destroying infected cells, and may be used after the patient has been infected.
Watch the video below to learn more about how our targeted T-cell immunotherapy delivery platform works.
Prevention and Treatment
Vaccines for COVID-19 have been delayed and their efficacy has not yet been determined.
Opportunity for FLOVID-20
Currently, there is no treatment option for a patient with a positive COVID-19 test that is not yet sick. FLOVID-20 is specifically designed to fill this treatment void.
Hospitalization and Therapy
Therapeutics for very sick patients are slowly advancing. Patients would prefer treatment before they become sick.